Cramer: Apple Is Th...
Health Care: Drugs
Allos Therapeutics Inc. (ALTH: NASDAQ)
$1.77 -0.01 | -0.56%
06/01/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 28.50 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | 189.00 | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | 18.60 | 12.50 |
| Beta | 0.32 | 0.62 | 0.98 |
| Price to Sales (TTM) | 2.47 | 4.29 | 1.42 |
| Price to Book (MRQ) | 2.67 | 4.39 | 2.41 |
| Price to Tangible Book (MRQ) | 2.86 | 14.20 | 5.08 |
| Price to Cash Flow (TTM) | -7.50 | 19.50 | 9.80 |
| Price to Free Cash Flow (TTM) | 13.50 | -327.00 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.90 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.80 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 42.32 | -0.76 |
| Payout Ratio (TTM) | 0.00 | 51.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 4.30 | 15.60 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 115.90 | 9.00 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 6.32 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | -2.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | -2.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | 24.63 | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -51.43 | -6.43 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 5.20 | 1.30 | 1.10 |
| Current Ratio (MRQ) | 5.30 | 1.80 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.29 | 0.82 |
| Total Debt to Equity (MRQ) | 0.00 | 0.37 | 0.96 |
| Interest Coverage (TTM) | n.a. | 9.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 78.80 | 75.60 | 46.90 |
| Gross Margin - 5 Yr Avg | 74.20 | 75.30 | 47.70 |
| EBITD Margin (TTM) | -33.00 | 29.40 | 18.90 |
| EBITD - 5 Yr Avg | -374.60 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | -34.80 | 18.00 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 11.80 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -0.35 | 0.14 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 8.60 | 7.00 |
| Return on Assets (TTM) | -23.70 | 7.30 | 3.10 |
| Return on Assets - 5 Yr Avg | -47.90 | 4.60 | 2.50 |
| Return on Investment (TTM) | -37.00 | 10.40 | 7.90 |
| Return on Investment - 5 Yr Avg | -58.10 | 6.50 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 689,360.00 | 404,888.00 | 449,376.00 |
| Net Income/Employee (TTM) | -240,000.00 | 57,122.00 | 39,003.00 |
| Receivable Turnover (TTM) | 6.80 | 4.70 | 7.60 |
| Inventory Turnover (TTM) | 31.30 | 1.70 | 8.30 |
| Asset Turnover (TTM) | 0.70 | 0.60 | 0.40 |
Portfolios with ALTH
- Portfolio NameUser Type
- UserSaveyn walter
- ContributorStocks Under-$10 Setting Up...
- Userrab 's
- Usergdean1
- User$5 stocks
- UserStocks Under $5
- UserLegal Tender II
- UserTop Picks Under $5 for 2011...
- ContributorTop Stock Picks Under $5 fo...
- UserWatch List - Healthcare / B...
Latest ALTH Headlines from TheStreet
- Monday's Top 10 Articles, Videos on TheStreet 04.09.12 | 03:04 pm
- Spectrum Pharma: The Growth Party is Over 04.09.12 | 06:04 am
- Allos Stock Gaps Down On Today's Open (ALTH) 01.20.12 | 09:01 am
- Biotech Stock Mailbag: Amarin, Spectrum, Arena 01.06.12 | 06:01 am
- Spectrum Pharmaceuticals CEO: "We Are Always Looking for the Diamond in the Rough."
12.01.11 | 06:12 am - Next Step for Amag's Board: Fire CEO, Sell the Company. 10.21.11 | 11:10 am
- Biotech Stock Mailbag: Keryx Pharma 10.14.11 | 06:10 am
- Activist Fund Manager Ups Stake in Amag Pharma to Stop Merger With Allos 10.10.11 | 10:10 am
- Spectrum Pharma Said to Make Bid for Allos 09.21.11 | 11:09 am
- Biotech Stock Mailbag: Vivus 09.16.11 | 05:09 am
Press Releases for ALTH
- Allos Therapeutics (Graphic: Business Wire) - Business Wire 05.24.12 | 07:05 pm
- Spectrum Pharmaceuticals And Allos Therapeutics Announce Extension Of Previously Announced Tender Offer For Shares Of Allos Therapeutics - Business Wire 05.10.12 | 07:05 am
- Spectrum Pharmaceuticals Commences Tender Offer For All Outstanding Shares Of Allos Therapeutics - Business Wire 04.16.12 | 08:04 am
- Allos Therapeutics, Inc. (ALTH) Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Spectrum Pharmaceuticals - PR Newswire 04.05.12 | 10:04 am
- Spectrum Pharmaceuticals To Acquire Allos Therapeutics: Acquisition Expected To Be Accretive On A Cash Basis In Q4 Of 2012 - Business Wire 04.05.12 | 07:04 am
- Allos Therapeutics Reports Fourth Quarter And Full Year 2011 Financial Results - Business Wire 03.06.12 | 04:03 pm
- Allos Therapeutics To Report Fourth Quarter And Full Year 2011 Results On March 6, 2012 - Business Wire 02.21.12 | 08:02 am
- Allos Therapeutics Requests Re-Examination Of CHMP Opinion On FOLOTYN® In PTCL At The European Medicines Agency - Business Wire 01.30.12 | 08:01 am
- Allos Therapeutics Announces Interim Results From Phase 1 Combination Study Of FOLOTYN® And Bexarotene Demonstrate Activity In Patients With Relapsed Or Refractory Cutaneous T-cell Lymphoma - Business Wire 01.30.12 | 08:01 am
- Allos Therapeutics Receives Negative Opinion From The CHMP On FOLOTYN - Business Wire 01.20.12 | 07:01 am
Partner Headlines for ALTH
- Company News for April 9, 2012 - Corporate Summary - Zacks 04.09.12 | 10:04 am
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Benzinga's M&A Chatter for Thursday April 5, 2012 - Benzinga 04.08.12 | 01:04 pm
- Futures Steer Lower; Spectrum Pharmaceuticals Dives - Investor's Business Daily 04.05.12 | 09:04 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 03.30.12 | 09:03 am
- Allos Narrows Loss - Analyst Blog - Zacks 03.07.12 | 09:03 am
- ALTH Seeks Review of Folotyn Verdict - Analyst Blog - Zacks 02.06.12 | 06:02 pm
- Loss Shrinks at AMAG, CEO Departs - Analyst Blog - Zacks 11.08.11 | 10:11 am
- Company News for November 4, 2011 - Corporate Summary - Zacks 11.04.11 | 10:11 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 10.25.11 | 09:10 am
